Literature DB >> 10975597

Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischemic contracture in hyperthyroid hearts.

C I Pantos1, I S Mourouzis, S M Tzeis, V Malliopoulou, D D Cokkinos, P Asimacopoulos, H C Carageorgiou, D D Varonos, D V Cokkinos.   

Abstract

This study was undertaken to define the contributions of left ventricular hypertrophy (LVH) and increased adrenergic activity to the acceleration of ischemic contracture (IC) that occurs in chronic hyperthyroid rat heart. Acute and chronic hyperthyroidism (THYR) were induced by thyroxine administration for 2 and 14 days, respectively, and normal animals (NORM) served as controls. Isolated hearts were perfused in a Langendorff mode. NORM alpha acute, n = 6; THYR alpha acute, n = 8; and THYR alpha, n = 13; and NORM alpha, n = 13 were subjected to 20-min zero-flow global ischemia (I) and 45-min reperfusion (R). Additional THYR and NORM hearts treated with propranolol (prop) were subjected to 30-min I; THYR beta prop, n = 6 and NORM beta prop, n = 8, and THYR beta, n = 6, NORM beta, n = 8 served as controls. Acceleration of IC was measured by the time to peak contracture (Tmax). Left ventricular hypertrophy (LVH) was assessed by the ratio of left ventricular weight in milligrams (LVW) to animal body weight (BW) in grams. Cardiac hypertrophy developed in chronic but not acute hyperthyroidism. Propranolol reduced the extent of LVH. Contracture occurred earlier in chronic than in acute hyperthyroid and normal hearts. Propranolol did not alter contracture. In conclusion, IC is accelerated by thyroxine administration, and this is probably not due to LVH or increased beta-adrenergic activity. Propranolol diminishes LVH in hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975597     DOI: 10.1097/00005344-200009000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Modification of gene expression profiling related to renin-angiotensin system in an ischemia/reperfusion rat model after T3 infusion.

Authors:  Laura Sabatino; Silvana Balzan; Claudia Kusmic; Giorgio Iervasi
Journal:  Mol Cell Biochem       Date:  2018-05-08       Impact factor: 3.396

2.  Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart.

Authors:  Constantinos Pantos; Vassiliki Malliopoulou; Ioannis Paizis; Panagiotis Moraitis; Iordanis Mourouzis; Stylianos Tzeis; Evangelia Karamanoli; Demosthenes D Cokkinos; Hariclia Carageorgiou; Dennis Varonos; Dennis V Cokkinos
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

Review 3.  New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

Review 4.  Protection of the abnormal heart.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 5.  Rebuilding the post-infarcted myocardium by activating 'physiologic' hypertrophic signaling pathways: the thyroid hormone paradigm.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2008-09-05       Impact factor: 4.214

6.  The influence of hypoxia during different pregnancy stages on cardiac collagen accumulation in the adult offspring.

Authors:  Lingxing Wang; Meimei Li; Ziyang Huang; Zhenhua Wang
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.